カテゴリー： Grand View Research, 世界, 医療/バイオ

世界のヒト免疫不全ウイルス（HIV）治療薬市場2023-2030：薬剤種類別、薬剤クラス別（侵入・融合阻害薬、プロテアーゼ阻害薬、インテグラーゼ阻害薬）、地域別

◆英語タイトル：Human Immunodeficiency Virus Therapeutics Market Size, Share & Trends Analysis Report By Drug Type, By Drug Class (Entry & Fusion Inhibitors, Protease Inhibitors, Integrase Inhibitors), By Region, And Segment Forecasts, 2023 - 2030

Grand View Researchが発行した調査報告書（GRV23NVB123）◆商品コード：GRV23NVB123
◆発行会社（リサーチ会社）：Grand View Research
◆発行日：2023年10月3日
◆ページ数：75
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後3営業日）
◆調査対象地域：グローバル
◆産業分野：医薬品
◆販売価格オプション（消費税別）
Single UserUSD5,950 ⇒換算￥904,400見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算￥1,056,400見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算￥1,360,400見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

ヒト免疫不全ウイルス（HIV）治療薬市場の成長と動向
Grand View Research, Inc.の最新レポートによると、ヒト免疫不全ウイルス（HIV）治療薬の世界市場規模は、2023年から2030年にかけて年平均成長率1.5%で拡大し、2030年には113億4,000万ドルに達する見込みです。HIVは、世界的に最も困難な公衆衛生問題の1つであり続けています。

市場成長を促進する主な要因としては、無防備な性行為、感染した体液や組織で汚染された針や注射器への曝露、感染リスク要因に関する認識不足などにより、特に若者の間でHIV感染の発生率が増加していることが挙げられます。英国を拠点とするHIV/エイズ慈善団体AVERTによると、2015年にHIVに罹患した推定患者数は3,500万人以上と記録されています。

HIVは、発展途上国や低開発国、主にアジアやアフリカ地域の人々に大きな影響を与えています。この感染症は現在のところ治癒不可能であるため、抗レトロウイルス療法の主な目的は、作用機序に基づいて6つの異なる薬物クラスに分類される抗レトロウイルス薬を使用して、患者のウイルス複製を抑制することです。

併用療法では、各クラスがHIVのライフサイクルにおける異なるステップを標的とするため、少なくとも2～3種類の薬剤を使用します。薬剤の組み合わせは、患者の病歴、抗レトロウイルス薬の副作用に対する素因、他の疾患との重複感染などに基づいて選択されます。

ヒト免疫不全ウイルス（HIV）治療薬市場レポートハイライト

- インテグラーゼ阻害薬セグメントは、Gilead Sciences, In.やMerck & Co., Inc.などの大手企業によるインテグラーゼ阻害薬の追加発売が期待されることから、抗レトロウイルス薬の中で最も急成長するクラスと予想されます。

- 2022年の市場シェアは北米が51.5%超で最大です。診断施設へのアクセスが容易であることが、この地域の市場拡大を支える主な要因のひとつです。

- アジア太平洋地域は最も急成長している地域セグメントであり、医療インフラの充実と成長を後押しする適切な政府施策の存在により、予測期間中もその地位を維持すると予測されています。

- 2015年のヒト免疫不全ウイルス（HIV）治療薬分野では、ギリアド・サイエンシズ社が市場シェアと医薬品ポートフォリオで首位に立ち、ヴィーブヘルスケア社がこれに続きました。さらに、今後数年間で、他の小規模プレーヤーがパイプライン医薬品でこの分野に参入すると予想されています。

- この業界の他の重要なプレーヤーには、AbbVie, Inc.、Bristol-Myers Squibb Company、Merck & Co.などが挙げられます。

第1章. 調査方法・範囲
第2章. エグゼクティブサマリー
第3章. ヒト免疫不全ウイルス（HIV）治療薬の市場変数・傾向・範囲
第4章. ヒト免疫不全ウイルス（HIV）治療薬の世界市場：薬剤種類別予測・傾向分析
第5章. ヒト免疫不全ウイルス（HIV）治療薬の世界市場：薬剤クラス別予測・傾向分析
第6章. ヒト免疫不全ウイルス（HIV）治療薬の世界市場：地域別予測・傾向分析
第7章. 競争状況

❖ レポートの目次 ❖

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Drug type
1.1.2. Drug class
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Drug type outlook
2.2.2. Drug class outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Human Immunodeficiency Virus Therapeutics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Human Immunodeficiency Virus Therapeutics: Market Analysis Tools
3.4.1. Industry Analysis – Porter’s Five Forces
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Human Immunodeficiency Virus Therapeutics Market: Drug Type Estimates & Trend Analysis
4.1. Human Immunodeficiency Virus Therapeutics Market: Key Takeaways
4.2. Human Immunodeficiency Virus Therapeutics Market: Drug Type Movement & Market Share Analysis, 2022 & 2030
4.3. Branded Drugs
4.3.1. Branded drugs market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Generic Drugs
4.4.1. Generic drugs market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Human Immunodeficiency Virus Therapeutics Market: Drug Class Estimates & Trend Analysis
5.1. Human Immunodeficiency Virus Therapeutics Market: Key Takeaways
5.2. Human Immunodeficiency Virus Therapeutics Market: Drug Class Movement & Market Share Analysis, 2022 & 2030
5.3. Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
5.3.1. Nucleoside-analog reverse transcriptase inhibitors (NRTIs) market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
5.4.1. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Entry and Fusion Inhibitors
5.5.1. Entry and fusion inhibitors market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. Protease Inhibitors (PIs)
5.6.1. Protease inhibitors (PIs) market estimates and forecasts, 2018 to 2030 (USD Million)
5.7. Integrase Inhibitors
5.7.1. Integrase inhibitors market estimates and forecasts, 2018 to 2030 (USD Million)
5.8. Coreceptor Antagonists
5.8.1. Coreceptor antagonists market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Human Immunodeficiency Virus Therapeutics Market: Regional Estimates & Trend Analysis
6.1. Regional Outlook
6.2. Human Immunodeficiency Virus Therapeutics Market by Region: Key Takeaways
6.3. North America
6.3.1. North America market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.3.2. U.S.
6.3.2.1. U.S. market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.3.3. Canada
6.3.3.1. Canada market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4. Europe
6.4.1. Europe market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.2. UK
6.4.2.1. UK market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.3. Germany
6.4.3.1. Germany market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.4. France
6.4.4.1. France market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.5. Italy
6.4.5.1. Italy market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.6. Spain
6.4.6.1. Spain market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.7. Sweden
6.4.7.1. Sweden market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.8. Norway
6.4.8.1. Norway market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.9. Denmark
6.4.9.1. Denmark market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5. Asia Pacific
6.5.1. Asia Pacific market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.2. Japan
6.5.2.1. Japan market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.3. China
6.5.3.1. China market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.4. India
6.5.4.1. India market estimates and forecasts, 2018 – 2030 (USD Million) (Revenue, USD Million)
6.5.5. Australia
6.5.5.1. Australia market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.6. Thailand
6.5.6.1. Thailand market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.7. South Korea
6.5.7.1. South Korea market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.6. Latin America
6.6.1. Latin America market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.6.2. Brazil
6.6.2.1. Brazil market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.6.3. Mexico
6.6.3.1. Mexico market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.6.4. Argentina
6.6.4.1. Argentina market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7. MEA
6.7.1. MEA market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7.2. Saudi Arabia
6.7.2.1. Saudi Arabia market estimates and forecasts, 2018 – 2030 (USD Million) (Revenue, USD Million)
6.7.3. South Africa
6.7.3.1. South Africa market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7.4. UAE
6.7.4.1. UAE market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7.5. Kuwait
6.7.5.1. Kuwait market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Market Participant Categorization
7.2.1. AbbVie Inc.
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. Boehringer Ingelheim International GmbH
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Bristol-Myers Squibb Company
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Cipla Inc.
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Genentech, Inc.
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. Gilead Sciences, Inc.
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Merck & Co., Inc.
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. ViiV Healthcare
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives

List of Tables

Table 1 List of Abbreviations
Table 2 North America human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 3 North America human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 4 North America human immunodeficiency virus therapeutics market, by region, 2018 - 2030 (USD Million)
Table 5 U.S. human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 6 U.S. human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 7 Canada human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 8 Canada human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 9 Europe human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 10 Europe human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 11 Europe human immunodeficiency virus therapeutics market, by region, 2018 - 2030 (USD Million)
Table 12 Germany human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 13 Germany human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 14 UK human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 15 UK human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 16 France human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 17 France human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 18 Italy human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 19 Italy human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 20 Spain human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 21 Spain human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 22 Sweden human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 23 Sweden human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 24 Norway human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 25 Norway human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 26 Denmark human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 27 Denmark human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 28 Asia Pacific human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 29 Asia Pacific human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 30 Asia Pacific human immunodeficiency virus therapeutics market, by region, 2018 - 2030 (USD Million)
Table 31 China human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 32 China human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 33 Japan human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 34 Japan human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 35 India human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 36 India human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 37 Australia human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 38 Australia human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 39 Thailand human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 40 Thailand human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 41 South Korea human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 42 South Korea human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 43 Latin America human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 44 Latin America human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 45 Latin America human immunodeficiency virus therapeutics market, by region, 2018 - 2030 (USD Million)
Table 46 Brazil human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 47 Brazil human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 48 Mexico human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 49 Mexico human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 50 Argentina human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 51 Argentina human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 52 Middle East and Africa human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 53 Middle East and Africa human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 54 Middle East and Africa human immunodeficiency virus therapeutics market, by region, 2018 - 2030 (USD Million)
Table 55 South Africa human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 56 South Africa human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 57 Saudi Arabia human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 58 Saudi Arabia human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 59 UAE human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 60 UAE human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
Table 61 Kuwait human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 62 Kuwait human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 世界のヒト免疫不全ウイルス（HIV）治療薬市場2023-2030：薬剤種類別、薬剤クラス別（侵入・融合阻害薬、プロテアーゼ阻害薬、インテグラーゼ阻害薬）、地域別(Human Immunodeficiency Virus Therapeutics Market Size, Share & Trends Analysis Report By Drug Type, By Drug Class (Entry & Fusion Inhibitors, Protease Inhibitors, Integrase Inhibitors), By Region, And Segment Forecasts, 2023 - 2030)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 世界の特発性血小板減少性紫斑病（ITP）治療薬市場2023-2030：疾患種類別（副腎皮質ステロイド、IVIG、抗D免疫グロブリン、TPO-RA、その他）、地域別
  • 世界のアトピー性皮膚炎治療薬市場2023-2030：薬剤クラス別（生物学的製剤、PDE4阻害剤、副腎皮質ホルモン、カルシニューリン阻害剤）、投与経路別（局所、注射、経口）、地域別
  • 世界の肝がん治療薬市場2023-2030：薬剤クラス別（標的療法、免疫療法、化学療法）、地域別
  • 大腸がん治療薬の世界市場2023-2030：市場規模、シェア、動向分析

    • ◆H&Iグローバルリサーチのお客様（例）◆